Format

Send to

Choose Destination
Leukemia. 2019 May;33(5):1301-1302. doi: 10.1038/s41375-019-0432-x. Epub 2019 Mar 6.

Response to the Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma".

Author information

1
Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. barosig@smatteo.pv.it.
2
Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College, London, London, UK.
PMID:
30842607
DOI:
10.1038/s41375-019-0432-x

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center